New Delhi: For decades, a diagnosis of high-grade glioma, one of the most aggressive forms of brain cancer, was associated with poor survival and limited treatment options. However, advances in molecular diagnostics, precision surgery, targeted therapies, and modern radiation techniques are steadily changing that outlook.
Improved Survival Rates
According to neuro-oncology experts, median survival among many high-grade glioma patients has improved from about 9-12 months to 14-18 months. Some centers are now reporting nearly 40% two-year survival among Grade-III and Grade-IV glioma patients, and a small subset of patients are surviving beyond a decade.
Expert Insights
Dr. Shyam Agarwal, senior consultant in medical oncology at Sir Ganga Ram Hospital, stated that the perception that a brain tumor diagnosis is invariably fatal is outdated. He emphasized that brain tumors can be benign or malignant, and even among malignant tumors, there are different grades. Today, multiple treatment options, including surgery, radiation, and targeted drugs, can control the disease for long periods and, in selected cases, even offer a cure.
Experts attribute better outcomes to improvements in surgery, radiation therapy, and molecular diagnostics. Dr. Amitabh Gupta, director of neurosurgery at PSRI Hospital, explained that technologies such as neuronavigation, operating microscopes, and fluorescent markers now allow surgeons to distinguish tumor tissue more accurately during surgery. These tools help maximize safe tumor removal while preserving healthy nervous tissue. Combined with stereotactic radiosurgery and molecularly guided chemotherapy, they are improving tumor control, survival, and quality of life. Even in recurrent tumors, repeat surgery along with chemo-radiosurgery is yielding encouraging results.
Dr. Tejinder Kataria, chairperson of radiation oncology at Medanta, noted that advances in radiation delivery have significantly improved outcomes for patients with high-grade gliomas. She highlighted that highly precise tumoricidal doses can now be delivered while protecting normal tissue. Median survival has improved from around 9-12 months to 14-18 months, with nearly 40% of Grade-III and -IV glioma patients surviving beyond two years, and some living for over a decade.
Role of Molecular Testing
Dr. Agarwal emphasized that molecular testing has become central to treatment planning. Comprehensive genomic profiling is increasingly essential. If an IDH1 mutation is identified, patients may benefit from targeted therapies such as Vorasidenib. Gene sequencing is helping doctors identify precision-medicine options that were not available a few years ago.
Dr. R. Ranga Rao, chairman of medical oncology at Paras Health, added that markers such as IDH mutations and MGMT status, along with comprehensive genomic sequencing, are helping identify patients who may benefit from targeted therapies. Precision diagnostics and multidisciplinary care are translating into longer survival and better quality of life.
Challenges and Future Directions
Despite these advances, delayed diagnosis remains a major challenge. Dr. Agarwal noted that symptoms such as persistent headaches are often treated as stress, migraine, or other common conditions, delaying diagnosis and treatment. Specialists are also reporting a growing number of younger adults presenting with gliomas and astrocytomas. Brain tumors account for around 2% of all cancers diagnosed in India, while gliomas and astrocytomas occur at an estimated rate of five to 10 cases per 1 lakh population annually.
Researchers believe the future lies in precision oncology and next-generation immunotherapies. Dr. Pranav Sopory, medical and patient affairs director at Servier India, said that treatment is moving away from a one-size-fits-all approach. Innovations such as targeted therapies, immunotherapy, and CAR-T cell research offer hope for better outcomes in the coming years.
